AB Science will participate in Biomed Forum Investors Conference in Paris on February 4.

From GlobeNewswire: 2025-01-22 13:00:01

AB Science SA will be participating in the Biomed Forum Investors Conference on February 4, 2025, in Paris. The company specializes in protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs. Their lead compound, masitinib, is being developed for various diseases. AB Science was founded in 2001 and is listed on Euronext Paris. The conference is organized by AllInvest Securities. Investors are cautioned about forward-looking statements in the press release, as results may differ from projections due to uncertainties in product development and marketing authorizations. Contact AB Science for more information.



Read more at GlobeNewswire: AB Science will participate in the Biomed Forum investors